The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors

• Published in: PloS one Vol. 15; no. 5; p. e0231999
• Main Authors: Rinaldi, Jacob, Sokol, Ethan S, Hartmaier, Ryan J, Trabucco, Sally E, Frampton, Garrett M, Goldberg, Michael E, Albacker, Lee A, Daemen, Anneleen, Manning, Gerard
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 06.05.2020; Public Library of Science (PLoS)
• Subjects: Adaptation; Bioinformatics; Biology; Biology and Life Sciences; Breast cancer; Breast tumors; Cancer genetics; Cancer metastasis; Cancer research; Cancer therapies; Clinical trials; Consent; Cyclin-dependent kinase 4; Cyclin-dependent kinases; Death; Deoxyribonucleic acid; DNA; Enrichment; Epidermal growth factor; Epidermal growth factor receptors; ESR1 protein; Genetic aspects; Genetic research; Genomics; Health aspects; Kinases; Ligands; Lungs; Medicine; Medicine and Health Sciences; Metastases; Metastasis; Mutation; Mutation hot spots; Pertuzumab; Proteins; PTEN protein; Skin; Tumors; United States; United States > US; South San Francisco California
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0231999

Metastatic breast cancer is the leading cause of cancer death in women, but the genomics of metastasis in breast cancer are poorly studied. We explored a set of 11,616 breast tumors, including 5,034 metastases, which had undergone targeted sequencing during standard clinical care. Besides the known hotspot mutations in ESR1, we observed a metastatic enrichment of previously unreported, lower-prevalence mutations in the ligand-binding domain, implying that these mutations may also be functional. Furthermore, individual ESR1 hotspots are significantly enriched in specific metastatic tissues and histologies, suggesting functional differences between these mutations. Other alterations enriched across all metastases include loss of function of the CDK4 regulator CDKN1B, and mutations in the transcription factor CTCF. Mutations enriched at specific metastatic sites generally reflect biology of the target tissue and may be adaptations to growth in the local environment. These include PTEN and ASXL1 alterations in brain metastases and NOTCH1 alterations in skin. We observed an enrichment of KRAS, KEAP1, STK11 and EGFR mutations in lung metastases. However, the patterns of other mutations in these tumors indicate that these are misdiagnosed lung primaries rather than breast metastases. An order-of-magnitude increase in samples relative to previous studies allowed us to detect novel genomic characteristics of metastatic cancer and to expand and clarify previous findings.